CPIC 2026 | The Chinese General Chamber of Commerce in Hong Kong and Hong Kong Biomedical Innovation Association Join Forces to Open a New Chapter for China’s National Pharmaceutical Power

Apr 17,2026

The inaugural China Pharmaceutical Innovation Congress (CPIC) 2026, hosted by Tongxieyi, will be grandly held at the National Exhibition and Convention Center (Shanghai) from July 22 to 24, 2026.
 
Modeled after the J.P. Morgan Healthcare Conference in the U.S., CPIC establishes an innovative paradigm of “China Innovation – Global Translation – Shanghai Deal-Making”. As the premier window for overseas capital and enterprises to gain insights into China’s innovation ecosystem, and the core hub for Chinese pharmaceutical companies to upgrade their global outreach and connect with the world, the China Pharmaceutical Innovation Congress is set to become the bellwether event for healthcare industry investment and cooperation annually. The congress will feature dozens of thematic sessions covering a wide range of hot topics and future directions in healthcare innovation, investment and globalization.
 
The CPIC Organizing Committee officially announces that The Chinese General Chamber of Commerce in Hong Kong and Hong Kong Biomedical Innovation Association have joined hands as co-organizers of the inaugural China Pharmaceutical Innovation Congress. Together with Tongxieyi, they will co-launch the CPIC Hong Kong Session.
 
Based in Hong Kong and connected to the world, the session will foster an in-depth cooperation and exchange platform between the Chinese mainland, Hong Kong and international markets, and jointly advance the internationalization journey of China’s biopharmaceutical industry.
 

Scan the QR code to register now!
Limited-time early bird tickets at 40% off – grab yours now!!
The overseas registration link will be available soon. Stay tuned!

 

About Hong Kong Chinese Industry & Commerce Association (HKCICA)
 

Founded in 1996 and headquartered in Wan Chai, Hong Kong, the Hong Kong Chinese Industry & Commerce Association (HKCICA) is a leading non‑profit Chinese commercial organization in Hong Kong. Guided by the mission of “Patriotic and Loving Hong Kong, Promoting Business and Commerce”, the Association now has over 6,000 member enterprises spanning diverse sectors including finance, technology, logistics, and more. It hosts more than 20 specialized committees covering finance, technological innovation, aerospace, and other fields.

 

As a bridge connecting Hong Kong, the Chinese Mainland and the world, the Association actively organizes economic and trade exchanges and investment promotion activities to support members in expanding domestic and international markets. It also serves as an economic advisor to multiple provinces and cities in the Mainland.

 

In 2022, with the approval of the Ministry of Public Security of the People’s Republic of China, the Association was registered as an overseas non‑governmental organization and established its Shanghai Representative Office in the Hongqiao International Central Business District. It regularly conducts overseas trade matchmaking events and sci‑tech industry forums, builds a cross‑border business cooperation network, and contributes to Hong Kong’s prosperity and national development.

 

 

 

About Hong Kong Biomedical Innovation Association

 

The Hong Kong Biomedical Innovation Association is committed to establishing an innovative and international biotech platform for Hong Kong.

 

Since its establishment, the Association has proactively facilitated the introduction of top-tier overseas biomedical innovation projects. Leveraging its self-built industrial ecosystem, it provides end-to-end support for projects entering the Chinese Mainland and Asian markets, covering key areas including but not limited to industrialization planning, financing and listing, corporate governance, patent protection, regulatory compliance, valuation, and clinical trial design.

 

Our mission is to promote communication, exchange and cooperation among the biomedical innovation industry, research institutions, investment communities and government organizations in R&D innovation, industrialization, regulatory policy, investment and financing.

 

 

About TONACEA

 

TONACEA is a premier ecosystem platform in China's biomedical innovation sector. With over 20 years of deep engagement in China's innovative drug development, it has grown into a key organizational force driving China's pharmaceutical innovation and serves as a core hub connecting multinational pharmaceutical companies with local innovation.

 

TONACEA brings together multinational pharmaceutical companies, biotech firms, investment institutions, research institutes, and regulatory experts, establishing a high-end professional network and knowledge-sharing system that covers the entire R&D value chain. Its business encompasses industry summits, technical forums, customized corporate training, media communications, and strategic consulting. With multiple branches across China, TONACEA has built an operational network that extends nationwide. Its official WeChat account and video channel consistently deliver in-depth industry insights, with perspectives frequently cited by investors and media, earning recognition as a trusted authoritative source within the industry.